Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Sponsor: Genentech, Inc.
This EARLY_PHASE1 trial investigates Breast Neoplasms and is currently completed. Genentech, Inc. leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Completed EARLY_PHASE1
-
Oct 2019 — Oct 2020 [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Dec 2018 — Oct 2019 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting EARLY_PHASE1
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — May 2017 [monthly]
Recruiting EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting Phase 0
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- GlaxoSmithKline
- Susan G. Komen Breast Cancer Foundation
- UNC Lineberger Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .